Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aptevo Therapeutics

0.5025
-0.0635-11.22%
Volume:815.64K
Turnover:412.19K
Market Cap:2.79M
PE:-0.01
High:0.5750
Open:0.5750
Low:0.4964
Close:0.5660
Loading ...

Aptevo Therapeutics announces results from cohort 1 in frontline AML trial

TIPRANKS
·
12 Dec 2024

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

ACCESSWIRE
·
12 Dec 2024

BRIEF-Aptevo Therapeutics Announces Details On Preclinical Bispecific Antibody APVO442

Reuters
·
04 Dec 2024

Aptevo Therapeutics Inc - Announces Details on Preclinical Bispecific Antibody Apvo442

THOMSON REUTERS
·
04 Dec 2024

Aptevo Therapeutics announces additional details about APVO442

TIPRANKS
·
04 Dec 2024

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

ACCESSWIRE
·
04 Dec 2024

Aptevo Therapeutics trading halted, news pending

TIPRANKS
·
04 Dec 2024

Top Midday Decliners

MT Newswires Live
·
30 Nov 2024

Aptevo Therapeutics Announces 1-for-37 Reverse Stock Split

MT Newswires Live
·
29 Nov 2024

BRIEF-Aptevo Therapeutics Announces 1-For 37 Reverse Stock Split As Part Of Nasdaq Compliance Plan

Reuters
·
29 Nov 2024

Aptevo Therapeutics announces 1-for-37 reverse stock split

TIPRANKS
·
29 Nov 2024

Aptevo Therapeutics Inc - Announces 1-for 37 Reverse Stock Split as Part of Nasdaq Compliance Plan

THOMSON REUTERS
·
29 Nov 2024

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

ACCESSWIRE
·
29 Nov 2024

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

ACCESSWIRE
·
26 Nov 2024

Aptevo Therapeutics highlights potential of portfolio in cancer immunotherapy

TIPRANKS
·
22 Nov 2024

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

ACCESSWIRE
·
22 Nov 2024

Sector Update: Health Care Stocks Advance Wednesday Afternoon

MT Newswires Live
·
21 Nov 2024

Aptevo Therapeutics Shares Gain After First Dosed Patient in AML Trial Shows 90% Reduction in Leukemic Blasts

MT Newswires Live
·
20 Nov 2024

BRIEF-First Patient Dosed In Ongoing Rainier Trial Achieved 90% Reduction In Leukemic Blasts Within The First 30 Days Of Treatment

Reuters
·
20 Nov 2024

Aptevo Therapeutics - Favorable Early Safety, Efficacy, Tolerability,Durability of Remission Data Informed Co's Ongoing Rainier Phase 1B/2 Trial

THOMSON REUTERS
·
20 Nov 2024